

Optimizing detection and prediction of cognitive function in multiple sclerosis with ambulatory cognitive tests: Protocol for the longitudinal observational “CogDetect-MS” study

Anna Louise Kratz, Dawn M. Ehde, Kevin N. Alschuler, Kristen Pickup, Keara Ginell, Nora E. Fritz

Submitted to: JMIR Research Protocols
on: April 24, 2024

Disclaimer: © The authors. All rights reserved. This is a privileged document currently under peer-review/community review. Authors have provided JMIR Publications with an exclusive license to publish this preprint on its website for review purposes only. While the final peer-reviewed paper may be licensed under a CC BY license on publication, at this stage authors and publisher expressly prohibit redistribution of this draft paper other than for review purposes.

Table of Contents

Original Manuscript..... 5

Supplementary Files..... 36

Figures 37

 Figure 1..... 38

 Figure 2..... 39

 Figure 3..... 40

 Figure 4..... 41

Multimedia Appendixes 42

 Multimedia Appendix 1..... 43

 Multimedia Appendix 2..... 43

 Multimedia Appendix 3..... 43

Optimizing detection and prediction of cognitive function in multiple sclerosis with ambulatory cognitive tests: Protocol for the longitudinal observational “CogDetect-MS” study

Anna Louise Kratz¹ PhD; Dawn M. Ehde² PhD; Kevin N. Alschuler² PhD; Kristen Pickup³ MSW; Keara Ginell³ BA; Nora E. Fritz⁴ PhD

¹Department of Rehabilitation Medicine University of Washington Seattle US

²Department of Physical Medicine and Rehabilitation University of Michigan Ann Arbor US

³Departments of Health Care Sciences and Neurology Wayne State University Detroit US

Corresponding Author:

Anna Louise Kratz PhD

Abstract

Background: Cognitive dysfunction is a common, distressing, and disabling problem in multiple sclerosis (MS). Progress toward understanding and treating cognitive dysfunction is thwarted by limitations of traditional clinic or lab-based cognitive tests, which suffer from poor sensitivity to change and ecological validity. Ambulatory methods of assessing cognitive function in the lived environment offer the potential to improve detection of subtle changes in cognitive function in MS and better understand the predictors of cognitive changes and downstream effects of cognitive change on other functional domains.

Objective: This paper describes the study design and protocol for the CogDetect-MS study, a 2-year longitudinal observational study designed to examine short- and long-term changes in cognition, predictors of cognitive change, and effects of cognitive change on social and physical function in people with MS.

Methods: Participants – ambulatory adults ages 18 years or older with medically documented MS - are assessed over the course of two years on an annual basis (three assessments total: T1, T2, T3). A comprehensive survey battery, in-lab cognitive and physical performance tests, and 14 days of ambulatory data collection are completed at each annual assessment. The 14-day ambulatory data collection includes continuous wrist-worn accelerometry (to measure daytime activity and sleep) and ecological momentary assessments (real-time self-report) of somatic symptoms, mood, and contextual factors and 2 brief, validated cognitive tests, administered by smartphone app 4 times per day. Our aim was to recruit 250 adults with MS.

Results: The study has recruited and collected T1 data from N=260 adults with MS. Follow-up data collection will continue through March 2026.

Conclusions: Results from the CogDetect-MS study will shed new light on the temporal dynamics of cognitive function, somatic and mood symptoms, sleep, physical activity, and physical and social function. These insights have the potential to improve our understanding of changes in cognitive function in MS and enable us to generate new interventions to maintain or improve cognitive function in those with MS. Clinical Trial: NCT05252195

(JMIR Preprints 24/04/2024:59876)

DOI: <https://doi.org/10.2196/preprints.59876>

Preprint Settings

1) Would you like to publish your submitted manuscript as preprint?

✓ **Please make my preprint PDF available to anyone at any time (recommended).**

Please make my preprint PDF available only to logged-in users; I understand that my title and abstract will remain visible to all users.

Only make the preprint title and abstract visible.

No, I do not wish to publish my submitted manuscript as a preprint.

2) If accepted for publication in a JMIR journal, would you like the PDF to be visible to the public?

✓ **Yes, please make my accepted manuscript PDF available to anyone at any time (Recommended).**

Yes, but please make my accepted manuscript PDF available only to logged-in users; I understand that the title and abstract will remain visible to all users.
Yes, but only make the title and abstract visible (see Important note, above). I understand that if I later pay to participate in <http://www.jmir.org/preprint/59876>, the full manuscript will be available to all users.



Original Manuscript

Optimizing detection and prediction of cognitive function in multiple sclerosis with ambulatory cognitive tests: Protocol for the longitudinal observational “CogDetect-MS” study

Anna L. Kratz¹, Dawn M. Ehde², Kevin N. Alschuler², Kristen Pickup¹, Keara Ginell¹,

& Nora E. Fritz³

Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, Michigan, USA

Department of Rehabilitation Medicine, University of Washington, Seattle, Washington, USA

Departments of Health Care Sciences and Neurology, Wayne State University, Detroit, Michigan, USA

Corresponding Author:

Anna L. Kratz
Department of Physical Medicine and Rehabilitation
University of Michigan
2800 Plymouth Road
North Campus Research Complex
Building 16, Room G17-W
Ann Arbor, MI 48109
Phone: 734-647-5982
Email: alkratz@umich.edu

Abstract

Background: Cognitive dysfunction is a common, distressing, and disabling problem in multiple sclerosis (MS). Progress toward understanding and treating cognitive dysfunction is thwarted by limitations of traditional clinic or lab-based cognitive tests, which suffer from poor sensitivity to change and ecological validity. Ambulatory methods of assessing cognitive function in the lived environment offer the potential to improve detection of subtle changes in cognitive function in MS and better understand the predictors of cognitive changes and downstream effects of cognitive change on other functional domains.

Objective: This paper describes the study design and protocol for the CogDetect-MS study, a 2-year longitudinal observational study designed to examine short- and long-term changes in cognition, predictors of cognitive change, and effects of cognitive change on social and physical function in people with MS.

Methods: **Participants** – ambulatory adults ages 18 years or older with medically documented MS - are assessed over the course of two years on an annual basis (three assessments total: T1, T2, T3). A comprehensive survey battery (demographics, clinical characteristics, medical history, and self-report measures), in-lab cognitive and physical performance tests (NIH Toolbox Cognitive & Motor, backward walking, and pen-and-paper cognitive tests), and 14 days of ambulatory data collection are completed at each annual assessment. The 14-day ambulatory data collection includes continuous wrist-worn accelerometry (to measure daytime activity and sleep) and ecological momentary assessments (real-time self-report) of

somatic symptoms, mood, and contextual factors and 2 brief, validated cognitive tests, administered by smartphone app 4 times per day. Our aim was to recruit 250 adults with MS. To ensure standard test protocol administration across study sites and time, all examiners passed a rigorous examiner certification process. Planned analyses include a) non-parametric t-tests to compare in-person to ambulatory cognitive test scores, b) mixed effects models to examine cognitive changes over time, c) mixed effects multilevel models to evaluate whether ambulatory measures of physical activity, sleep, fatigue, pain, mood and stress predict changes in objective or subjective measures of cognitive functioning, and d) mixed effects multilevel models to examine whether ambulatory measures of cognitive functioning predict social and physical functioning over short (within-day) and long (over years) time frames.

Results: The study has recruited and collected T1 data from N=260 adults with MS. Follow-up data collection will continue through March 2026.

Conclusions: Results from the CogDetect-MS study will shed new light on the temporal dynamics of cognitive function, somatic and mood symptoms, sleep, physical activity, and physical and social function. These insights have the potential to improve our understanding of changes in cognitive function in MS and enable us to generate new interventions to maintain or improve cognitive function in those with MS.

Study Registration: NCT05252195

Keywords: ambulatory assessment; longitudinal data collection; ecological momentary assessment; cognitive function; cognitive assessment; multiple sclerosis, physical activity; neuropsychology

Introduction

Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune disease of the brain and spinal cord that affects approximately 1 million people in the US [1]. It is the #1 cause of non-traumatic disability in young adults [2]. Cognitive dysfunction is one of the most common problems in MS; up to 70% of people with MS report some type of cognitive dysfunction [3], including deficits in processing speed [4], episodic memory, visual memory, verbal fluency [5], working memory [6], and/or executive functioning [7]. Cognitive dysfunction in MS exerts a dire impact on many aspects of health-related quality of life, including employment, independent living, social participation, and physical functioning [8-10] and has been linked to poor treatment adherence [11]. Unfortunately, progress in developing preventative, compensatory and restorative interventions for cognition in MS is stymied by major gaps in our knowledge of the natural history of cognitive decline and of the characteristics and mechanisms of cognitive dysfunction where it matters most – in the everyday lives of people with MS [12].

Our knowledge of the nature and impact of cognitive functioning in MS is restricted by measurement limitations and insufficient attention to potential contributors to and consequences of changes in cognition. Measurement of cognitive function is limited by reliance on cross-sectional data and use of standard neuropsychological testing protocols. These assessment protocols are insensitive to subtle cognitive changes and suffer from practice effects, temporal bias, and poor ecological validity [13-15]. A crucial limitation is that the “snapshot” of cognitive function, typical of cross-sectional neuropsychology studies, fails to capture day-to-day and within-day variability in an individual’s cognitive function [16, 17]. Understanding such short-term variability in cognitive function in MS is important for three

key reasons: First, within-person fluctuations in cognitive performance may be an independent indicator of poor cognitive functioning [18, 19] and of vulnerability to future cognitive decline [20, 21]. Second, identifying time-varying modifiable factors that precede and predict changes in cognitive dysfunction can provide crucial clues about potentially productive targets for intervention, particularly real-time interventions that can have immediate effects. Finally, studying within-person covariation between cognitive function and other functional domains, such as social and physical function, can provide convincing evidence as to the contribution of cognitive dysfunction to important person-centered outcomes.

To address measurement limitations of gold standard neuropsychological testing, this study leverages technology-assisted ambulatory assessment techniques to provide a unique and multidimensional window into cognitive dysfunction in the everyday lives of people with MS. Multiple complementary ambulatory assessment strategies are employed. A customized smartphone app is used to administer a battery of objective ambulatory cognitive tests that are designed specifically for serial administration in the lived environment, as well as ecological momentary assessments (real-time assessment) of self-reported symptoms and functioning as a person goes about daily life, an approach that is not as subject to recall bias or memory decay [22]. The smartphone app is paired with accelerometer technology, which provides objective, continuous, and unobtrusive measures of physical activity during day and night (i.e., sleep). Ambulatory assessments are administered in a “measurement burst design,” incorporating bursts of intensive repeated assessment in people with MS over two weeks, with bursts repeated longitudinally, at baseline, and 1- and 2- year follow-up. The burst design provides two main benefits: improved detection of subtle long-term changes in cognitive functioning and ability to examine fine-grained temporal associations between fluctuations in daily experiences (e.g., pain, fatigue, stress) and cognitive function [23].

Using these innovative assessment methods, we aim to explore foundational questions that have yet to be examined in MS, such as the degree and prognostic utility of within-person lability in cognitive function. We will determine if ambulatory assessments are sensitive to subtle declines in cognitive functioning. We will also explore the impact of modifiable factors, such as sleep, physical activity, mood, and somatic symptoms on cognitive function. Finally, we will explore whether variability in cognitive functioning predicts short- and long-term changes in other patient-centered functional domains, social participation and physical functioning. In pursuit of these primary objectives, the study is designed to test three hypotheses: 1) Ambulatory measures of subjective and objective cognitive function will be more sensitive to longitudinal changes (over 2 years) in cognitive functioning compared to conventional clinic-based assessments; 2) Ambulatory measures of modifiable factors – physical activity, sleep, fatigue, pain, mood, and stress – predict short-term (same-day) and long-term (at 1- and 2-year follow-up) changes in cognitive functioning; and, 3) Ambulatory measures of cognitive functioning will predict social and physical functioning over short- (same-day) and long-term (at 1- and 2-year follow-up) time frames.

Methods

This study applies an observational design that combines micro-longitudinal (i.e., frequent, repeated “burst” measures across 14 consecutive days) and longitudinal (i.e. 1- and 2- year follow-up) data collection methods in an MS sample. Subject recruitment and data collection is conducted across three sites: the University of Michigan (UM; lead site and data coordinating center) in Ann Arbor, MI, Wayne State University (WSU) in Detroit, MI, and the University of Washington (UW) in Seattle, WA. Ambulatory data are managed by researchers at the

Pennsylvania State University, who return scored and combined ambulatory datasets to UM.

Ethics Approval

This multisite study has a single institutional review board approval from the medical IRB at UM (HUM00199732; Participating site approvals UM= HUM00213744; WSU=SITE00000462; UW=SITE00000461).

Study Sample and Recruitment

The aim was to recruit N=250 participants, with the expectation that n=210 would also provide data at the final (2-year) follow-up. Participants were recruited through existing participant registries, electronic health record queries, institution-specific subject-recruitment websites, clinic- and community-based recruitment, posting of flyers, and outreach to local partners, such as the local chapters of the National MS Society. Inclusion criteria (assessed by self-report) were: 1) 18 years of age or older; 2) able to fluently converse and read in English; 3) MS diagnosis (confirmed via medical record review; all relapsing and progressive subtypes included); and 4) able to ambulate either independently or with the use of a cane or walker (or similar device) for at least 50% of the time at baseline; participants who lose ability to ambulate over the course of the study are retained as this criteria only applies to initial enrollment. Exclusion criteria were: 1) MS relapse within the past 30 days (may become eligible after 30 days; criteria used at T1, T2, and T3); and, 2) inability to use study data collection tools (i.e., ActiGraph wGT3X, smart phone app; volunteers “pass” this final exclusion criterion by independently completing a trial of the ambulatory assessment battery during the laboratory visit).

Participant screening, enrollment, and data collection procedures

Volunteers underwent an initial pre-screening by telephone to determine general inclusion/exclusion criteria and were fully screened at the T1 lab visit to establish study eligibility. MS diagnosis was either pre-confirmed through medical record review or initially gathered by self-report and later confirmed through record review. Written informed consent procedures were either conducted virtually (via Zoom or telephone and signature obtained via e-consent in REDCapTM) prior to the T1 lab visit or in person at the lab visit.

Participation in this study involves assessments at baseline (T1), 1-year follow-up (T2) and 2-year follow-up (T3). Each assessment period includes a ~2.5 hour lab visit immediately followed by a 14-day ambulatory monitoring period (measurement “burst”). At each lab visit, certified examiners administer cognitive and physical function test batteries and demonstrate the use of a study-specific smartphone (programmed with data collection app) and an ActiGraph wGT3X-BT accelerometer for collection of ambulatory data. A battery of web-based self-report surveys are also completed at each time point, either prior to (within 30 days of lab visit) or during the lab visit.

During each ambulatory monitoring period, participants continuously wear an ActiGraph wGT3X-BT to passively collect physical activity data. At four intervals throughout the day (wake, midday, afternoon/evening, bedtime), participants complete a set of brief, valid, and reliable cognitive tests assessing processing speed and working memory[13] along with a battery of ecological momentary assessment (EMA; real-time self-report) measures of somatic symptoms, mood, functioning, behaviors, and context on the smartphone app. The wake up and bedtime assessments are initiated by the participant when waking up (i.e., waking, not necessarily getting out of bed) and going to bed (i.e., “lights out”, not necessarily when getting into bed). The other two assessments are prompted by an audible alert on a quasi-random schedule determined by their usual waking time. At the end of each home monitoring period,

participants return the ActiGraph wGT3X-BT and smartphone in a pre-paid mailer to the lab for data download.

Participants are compensated \$600 for full completion of the study (\$200 for each visit - T1, T2, T3). For those who do not complete the full study, the compensation schedule is as follows: \$50/lab visit and \$150/home monitoring period (for <14 days of data, compensation is graded, with \$4/day days 1-5, \$10/day days 6-10, \$20/day days 11-14).

Data Collection Platforms and Technology

Survey data is collected via a secure, study-specific REDCapTM website. REDCapTM is an open-source, secure, HIPAA compliant web based platform designed to support data capture for research studies. It has been designed specifically to protect patient privacy and confidentiality while assisting investigators in clinical research. REDCapTM provides an interface for data entry and validation, auditing features for tracking data manipulation, the ability to import data from external sources, calculated data fields, branching logic, and the capability to export data to many statistical packages. System level and application-level security include SSL encryption of internet traffic (https pages), hosting in a secure data center with nightly backup, fine-grained control over user rights, detailed audit trails, record locking, and de-identification features for data export. REDCapTM was initially developed by Vanderbilt University, but now has collaborative support from a wide consortium of many domestic and international partners.

Self-report EMAs and ambulatory cognitive tests are administered via a customized application (**Figure 1**; Wear-IT, developed by the Real Time Science Lab, Pennsylvania State University, State College, PA) installed on a Motorola g⁸ Power mobile phone with a 6.4" display (1080 x 2300 pixels). The phone is loaned to participants for use during the study; it is not associated

with any phone number, and is used with an inactive SIM card for keeping accurate time on the phone; thus, there are no signals sent/received via the phone. Phones are loaned to study participants to ensure device consistency across participants and across time periods and because ambulatory cognitive assessment apps on personal phones have not been validated at the time the study launched. Response times are recorded in milliseconds. Data are stored onboard the smart phone until it is returned to the lab for data download.




Figure 1. The Wear-IT application landing page (A), morning survey landing page (B), self-reported wake up time (C), an item from the perceived cognitive function scale (D), an item from the depressed mood scale (E), and the survey of substance consumption (F).

The ActiGraph wGT3X-BT triaxial accelerometer (Actigraph, Pensacola, FL; **Figure 2**) is used to measure physical activity. It is mounted on a fabric band on the non-dominant wrist. In cases of



Figure 2. The ActiGraph wGT3X-BT triaxial accelerometer.

hemiparesis, the accelerometer is placed on the non-paretic side. It is lightweight (19 grams), compact (3.3 x 4.6 x 1.5 cm), and measures movement using a capacitive accelerometer that digitizes a voltage detected from movement at a sampling rate of 30Hz. The samples are summed over a 60-second epoch period and output as activity counts. Higher activity counts relate to more physical activity. We use a wrist-worn placement as this placement has been used extensively in physical activity studies and to validate the ActiGraph in MS [24-35].

Smartphone app data (EMA and cognitive tests) is combined and time synced with accelerometer data by the Wear-IT team.

CogDetect-MS Study Measures

Lab Visit Measures:

Self-Report Measures

The self-report survey battery includes surveys of demographics, clinical characteristics, and medical history (e.g., medications and therapies), and a selection of valid and reliable self-report measures (**Table 1 and Multimedia Appendix 1**).

Table 1. Validated self-report surveys administered in CogDetect-MS

Domain	Measure(s)
Sleep	PROMIS Sleep Disturbance SF 8b[56] STOP-Bang[57]
Fatigue	PROMIS Fatigue Short Form 8 V1.0[58] Michigan Fatigability Index Short Forms
Pain	PROMIS Pain Intensity 3a[56] PROMIS Pain Interference 8a[59-61] painDETECT[62] American College of Rheumatology Fibromyalgia Diagnostic Criteria[63, 64]
Depressed Mood	PROMIS Depression 8b[65]
Stress	Perceived Stress Scale [66]
Social Functioning	Neuro-QoL Ability to Participate in Social Roles & Activities Short Form 8[67, 68]
Cognitive Function	PROMIS Cognitive Abilities Short Form 8[69] Compensatory Cognitive Strategies Scale[70]
Physical Functioning	Neuro-QoL Upper Extremity Function-8[67] Neuro-QoL Lower Extremity Function-8[67] Patient Determined Disease Steps[71]
Falls	1-Month Falls History Falls Efficacy Scale[72] Fear of Falling Avoidance Behavior Questionnaire[73] Concern and Fear of Falling Evaluation [38, 74]
Substance Use	Tobacco, Alcohol, Prescription Medications, and Other Substances Tool[75-77]
Comorbidities	Comorbidity Questionnaire[78]
Personality^a	Ten-Item Personality Inventory[79]
Demographic & Clinical variables	Demographic & clinical characteristics survey Pet ownership survey[80]
Note. PROMIS = Patient Reported Outcomes Measurement Information System; ^a = evaluated at T1 visit only.	

Performance-
based lab
measures

Motor Function:

We administer
the full lower-

extremity and upper extremity NIH-Toolbox (NIHTB) motor test battery [36, 37] via the NIHTB iPad Application. In addition to the NIHTB motor measures, we also administer a 4-Meter Backward Walking Test to calculate backward walking speed [38-40]. See **Table 2** for full list of motor tests and **Multimedia Appendix 2** for further details.

Cognitive Function: We administer the NIHTB cognitive test battery plus the supplemental NIHTB Oral Symbol Digit Test [36, 41] via the NIHTB iPad Application. We also administer the Symbol Digit Modalities Test (oral administration) [42], the Paced Auditory Serial Addition Test (3 second) [43], the Rey Auditory Verbal Learning Test [44], and the ReacStick Test[45]. See **Table 2** for full list of lab-based cognitive tests and **Multimedia Appendix 2** for further

details.

Table 2. Cognitive and physical performance tests administered in CogDetect-MS

Domain	Measure(s)
Cognitive Function	Symbol Digit Modalities Test (oral administration) [42] Paced Auditory Serial Addition Test-3 second[43] ^a Rey Auditory Verbal Learning Test[44] ^a ReacStick Test[45] NIH Toolbox Cognitive Battery[36, 41]: -Dimensional Change Card Sort Test -Flanker Inhibitory Control and Attention Test -List Sorting Working Memory Test -Oral Reading Recognition Test -Oral Symbol Digit Test -Pattern Comparison Processing Speed Test -Picture Sequence Test ^a -Picture Vocabulary Test
Physical Function	4-Meter Backward Walking Test [39] NIH Toolbox Motor Battery[36, 37] -2-Minute Walk Endurance Test -4-Meter Walk Gait Speed Test -9-Hole Pegboard Dexterity Test -Grip Strength Test -Standing Balance Test
Note. ^a = alternate test forms used across T1, T2, T3; NIH = National Institutes of Health;	

Ambulatory

Measures

A set of EMA items

and scales (administered via smartphone app, 4X/day except where noted) are administered.

Some measures were adapted for daily administration from existing validated recall measures.

See Table 3 for full list of items and **Multimedia Appendix 3** for further details.

Table 3. Ambulatory data collected in CogDetect-MS

Data Type	Measure	Schedule
Ecological Momentary Assessment (via smartphone app)	Perceived Cognitive Function (3 items)	4X/day
	Pain Intensity (1 item)	4X/day
	Fatigue Intensity (2 items)	4X/day
	Perceived Stress (1 item)	4X/day
	Depressed Mood (3 items)	4X/day
	Location during cognitive tests (1 item)	4X/day
	Distractions during tests (4 items with branching logic)	4X/day
	Substance Use (1 item)	4X/day
	Activity Pacing (3 items)	3X/day ^a
	Sleep Quality (2 items)	Morning
	Overnight falls (4 items with branching logic)	Morning
	Social Participation (6 items)	Evening
	Physical Function (2 items)	Evening
	Daytime falls (4 items with branching logic)	Evening
Cognitive Function (via smartphone app)	Symbol Search Test	4X/day
	Dot Memory Test	4X/day

Physical Activity (via Actigraph accelerometer)	Daytime physical activity and nighttime sleep activity	Continuous 24 hours
Note. ^a = all time points except morning.		

Two brief, valid, and reliable cognitive tests[13] are administered via the smart phone app. Response time speed is recorded in milliseconds for all tests. The Symbol Search Test (**Figure 3**) is a test of processing speed. Participants see a row of 4 symbol pairs at the top of the screen and are presented with two symbol pairs at the bottom of the screen. Stimuli are presented until a response is provided. Participants decide, as quickly as possible, which symbol pair at the bottom matches one of the symbol pairs at the top and select the matching pair by touching their selection at the bottom. Twenty-four trials are administered for each session. Reaction time and errors are recorded for sessions where effort is deemed adequate (accuracy >70%).




Figure 3. Symbol Search landing page (A), test instructions (B and C), and examples of a “non-lure trial” (D; where neither symbol in the incorrect pair on the bottom appears in the pairs above) and a “lure trial” (E; where one of the symbols in the incorrect pair on the bottom appears in a pair above).

The Dot Memory Test (**Figure 4**) is a test of working memory. Each trial consists of 3 phases: encoding, distraction, and retrieval. During the encoding phase, the participant is asked to remember the location of three red dots appearing on 5X5 square grid. After a 3-second study period, the grid is removed and the distraction phase begins, during which the participant is

required to locate and touch the F's in an array of E's. After performing the distraction task, an empty 5X5 square grid is presented and the participant must place the red dots (by touching the empty squares) in the correct locations. Participants press "Done" when they are finished. Speed and Euclidian distance (a score of the collective distance of the three dots from their correct locations) are recorded. Four trials are administered for each session.




Figure 4. Dot Memory Test landing page (A), instructions (B), E's and F's distraction phase (C), and response page (D).

The ActiGraph produces variables representing different facets of day and nighttime physical activity. Our main measurements for daytime (awake) activity are activity counts, steps, physical activity intensity, and sedentary bouts across the 14-day home monitoring period, providing daily and typical activity levels. Our main measures for nighttime activity will be sleep latency, total sleep time, wake after sleep onset, and sleep efficiency.

Examiner Certification Process

To ensure standard test protocol administration across study sites and time, a rigorous examiner certification process was established. To achieve initial certification to administer tests, research staff were required to read the study protocol and manual of procedures, read the NIHTB Administrators Manual, watch all training videos, and pass quizzes at the end of

each training video. Training videos were from the NIH Toolbox eLearning Course or were custom made by the study investigators, who had expertise in motor testing (NEF) or neuropsychological test administration (ALK, DME, and KNA). The videos provide detailed instructions on general best practices for test administration and how to administer each non-NIHTB test. After these initial training activities, research staff practiced the full lab-visit protocol with at least 5 non-participants (e.g., fellow lab staff), video recording the final testing session. This video along with all accompanying case report forms and test materials were evaluated by two investigators – one with expertise in administering motor tests and one with expertise in administering neuropsychological tests. Together, the evaluators decided whether the examiner passed or failed the certification. Failure is defined as 2 or more minor errors or 1 or more major errors. A major error is defined as any error that indicates a lack of understanding of the proper standardized administration of any test or any scoring error that is large enough to change the interpretation of the data. Errors are reviewed with the examiner and their site PI. If the assessment is failed, the examiner practices at least one more time and submits a new certification video for review; this process can continue until the examiner passes certification. After initial certification, the examiner can begin testing study participants and is required to video record the first testing session with a person with MS; this video is also reviewed for consistency with study protocol and feedback shared with the examiner. To ensure continued adherence to testing protocol, examiners record the lab visit for every 10th session, and this recording is reviewed by investigators as with the earlier certification videos. Consent for video recording is included in the study consent form.

Data Monitoring

The Principal Investigators (ALK and NEF) and lead research coordinator from the data coordinating center (UM) conduct in-person data audits at each site on an annual basis. Data

related to adverse events, protocol deviations, study personnel training, screening procedures, subject withdrawal/termination, and enrollment procedures and documentation were audited for all subjects enrolled at the site; data related to eligibility screening and documentation, study visit tracking, subject contact information, human subjects compensation record, and data collection were audited for a random subsample of all subjects enrolled at the site. Audit reports, detailing findings and required responses to the audit were produced and delivered to the site PI and lead site research coordinator.

Multi-site coordination

To ensure multi-site coordination and fidelity of procedures, the full study team, including all examiners and investigators at all study sites met weekly to discuss study-related questions and to troubleshoot any issues that had arisen during the prior week for the first 18 months of the study. As fewer questions arose, and study teams were immersed in recruitment and testing, meetings were shifted to every other week (months 18-36). After Month 36, meetings were shifted to once per month. UM keeps a record of all meeting agendas and meeting minutes, and any clarifications to the study manual of procedures are recorded by the UM team and updated in a shared folder that includes all study-related documents.

UM serves as the data coordinating center for the study. Data from all sites are fully accessible to the investigators and staff at UM, who conduct monthly data checks to assess for data completeness and quality. Data double entry of case report forms from each study site and data cleaning, scoring, and merging to produce final, analyzable datasets are completed by UM staff and investigators.

Sample Size Analyses

We conducted analyses to determine the sample size needed to address all study aims. The

goal with the first study aim is to determine whether the ambulatory tests are able to detect cognitive decline from baseline (T1) to 1-year (T2) and/or 2-year follow-up (T3) for individuals where clinic-based tests do not detect decline. The proportion of participants who show (for any of the cognitive domains with ambulatory tests -working memory/attention, visual attention/processing speed, and inhibition/executive functioning) no decline/improvement, absolute but subtle decline (change $<1/2$ SD), meaningful decline (change between $1/2$ SD-1 SD)[46] or clinically significant decline (≥ 1 SD decline)[46, 47] will be calculated for both ambulatory and clinic-based neurocognitive tests. For each cognitive domain, a binary variable will be created for each participant indicating whether the ambulatory and clinic-based cognitive measures are consistent with each other (e.g., agree) about degree of change or lab-based or ambulatory measures indicate a larger degree of decline. We will test whether the proportion of cases where ambulatory measures indicated a larger degree of decline (relative to clinic-based tests) is statistically different from zero; sample size analyses for this test indicate that a sample of $N=199$ will have 95% power (with critical $\alpha=0.01$) to detect significance where ambulatory cognitive tests show greater level of decline compared to clinic-based tests in as few as 1.5% of cases. This suggests that our expected final sample size of $N=210$ has power to detect even modest differences in analyses comparing proportions of the sample for which the ambulatory cognitive tests indicate decline when the clinic-based tests do not.

Effects sizes from a prior study of perceived cognitive functioning in daily life in MS [48-50] informed sample size estimation for the second and third aims, which examines factors that predict later cognitive decline or that are predicted by cognitive changes. We calculated the sample size needed to test the aims in a linear regression framework [51], which is a relatively conservative estimate given that the repeated measures design imparts greater measurement

reliability and therefore greater power [52]. We based our estimates on models that included up to 6 covariates (see list of covariates below) and 6 predictor variables of interest (e.g., sleep quality, physical activity, pain, fatigue, mood, stress) in predicting any given cognitive variable. Sample size for these models was expected to provide a conservative estimate for power required for the third aim (which had fewer predictors in each model). Critical alpha (α) value was set at 0.01. Our analyses indicated that a sample size of 214 will have 95% power (critical $t = 2.34$, one-sided significance test) to detect an association between cognitive functioning and the variable expected to show the weakest association with cognition: mood (effect size $f^2 = 0.075$).

Data Analysis

Primary data analyses will account for covariates that have been shown to be associated with cognitive change in MS – age, sex, disease duration, MS subtype (relapsing vs. progressive subtypes combined), disease severity, personality variables, and cognitive reserve (education level plus scores on vocabulary test). After primary analyses are completed, analyses will be repeated stratifying by sex, age group, baseline cognitive impairment and MS subtype. We have intentionally included participants with both existing cognitive impairment and no known cognitive impairment at enrollment. This will allow us to also conduct sensitivity analyses to explore whether people who show evidence of cognitive impairment at baseline show a more rapid decline on either laboratory or ambulatory cognitive assessments as has been identified in prior research[53, 54].

Specific Aim 1: Are ambulatory measures of subjective and objective cognitive function more sensitive to longitudinal changes in cognitive function compared with conventional clinic-based assessments?

Non-parametric tests (Wilcoxon signed-rank test, 2-tailed) will be used to compare cognitive test scores (ambulatory versus clinic-based measures) for each participant at each time point. To test whether the proportion of cases where the ambulatory test indicates greater degree of cognitive decline compared to the clinic-based cognitive test, we will test whether that proportion is statistically different from zero. Additional sensitivity tests of the paired differences in proportions of four categories (no decline, absolute but subtle decline, meaningful decline, or clinically-significant decline) for each cognitive domain between ambulatory and clinic-based neurocognitive tests at both 1- and 2- year follow-up will be conducted [55]. Mixed effects models will be used to examine changes over time for each cognitive measure, with the expectation that the ambulatory measures will show larger time effects at both 1- and 2- year follow-up.

Specific Aim 2: Do modifiable factors predict short- and long-term changes in ambulatory measures of cognitive functioning?

Short-term: Mixed effects multilevel models (MLM) for momentary (within-day) associations, one for each ambulatory cognitive variable (perceived cognitive function, cognitive test scores), will be constructed. In each case, predictor variables of interest will be physical activity (accelerometer data), sleep (accelerometer data and EMA-sleep quality) and EMA measures of fatigue, pain, mood, and stress from the previous within-day time point (all moment-to-moment analyses will be conducted within-day). Similarly, MLMs for day-level associations, one for each cognitive variable will be constructed; only day-level analyses will explore the association between sleep and cognition. Given the lack of data on the temporal effects of these variables on cognitive functioning, exploratory analyses of lagged effects (1- and 2-day lag) effects will also be examined.

Long-term: Ambulatory measures of predictor and outcome variables will be aggregated within time period for baseline, and 1- and 2-year follow-up periods. Lab-based measures of cognitive

functioning will also be examined. MLMs will be used to test whether ambulatory measures of physical activity, sleep, fatigue, pain, mood, and stress predict changes in objective or subjective measures of cognitive functioning (ambulatory and lab-based measures) 1- or 2-years later. Change will be modeled within an ANCOVA framework where T2/T3 values for an outcome of interest are modeled controlling for T1 values of said outcome. In contrast to Specific Aim 1, where the primary interest is on comparing performance of the ambulatory tests to standard clinic-based cognitive tests, the primary interest of Specific Aim 2 is in understanding what factors contribute to variation/changes in cognitive function and in identifying probable targets for cognitive rehabilitation, regardless of the measure used to identify such associations; therefore, no direct comparisons between measurement types will be made.

Specific Aim 3: Do ambulatory measures of cognitive functioning predict social and physical functioning over short- and long- time frames?

Short-term: In the momentary data, MLMs will be constructed to predict same-day social participation and physical functioning (upper/lower-extremity functioning, balance, falls/missteps) from the ambulatory cognitive variables. Analyses for falls/near falls, will be conducted using a special case of MLM for categorical outcomes. Exploratory analyses of lagged effects (1- and 2-day lag) effects will also be examined.

Long-term: In terms of distal prediction of social and physical function from ambulatory cognition, we will conduct MLMs with the cognitive variables (averaged across each time period) predicting social and physical functioning at 1- and 2-year follow-up. Change will be modeled within an ANCOVA framework where T2/T3 values for an outcome of interest are modeled controlling for T1 values of said outcome. These MLMs exploring long-term associations between cognitive changes and changes in social and physical functioning will be repeated in a set of secondary analyses with standard clinic-based cognitive test scores as

predictor variables. Prediction of long-term changes in social and physical functioning from ambulatory cognitive measures will be compared to ability of lab-based measures to predict these same changes to examine which measures are better predictors of long-term changes in other functional domains. Ambulatory measures of cognition are of primary interest for Specific Aim 3 given that their micro-longitudinal burst design allows for examination of short- and long-term associations and are assumed to be more reliable and therefore more likely to demonstrate robust associations with the other functional outcomes.

Results

This research received funding on 08/01/2021 from the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD; R01HD102337-01A1). Enrollment and T1 data collection occurred between 05/12/2022 and 02/29/2024. The study recruited N=300 individuals with MS (UM n=107, WSU n=101, UW n=92); of these n=260 (UM n=92, WSU n=85, UW n=83) participated in T1 data collection. Longitudinal data collection will continue through March 2026. Data analysis has not yet started as of the time of this submission.

Discussion

The anticipated findings of this study are three-fold. First, we anticipate that ambulatory cognitive tests will be more sensitive to subtle cognitive changes in people with MS over 1-2 years. Second, we expect to identify modifiable factors (e.g., mood, sleep, physical activity) that precede and predict later cognitive decline on a short- and long-term scale. This information could help to prevent future decline or mitigate current cognitive dysfunction. Third, we hypothesize that cognitive changes will predict changes in social and physical function on a short- and long-term scale; such information will help to delineate the full impact of cognitive

change in MS.

The collection of intensive longitudinal data in a large, heterogenous sample will allow for an in-depth characterization of individuals with MS and provide multiple avenues for future research. Data from this study are expected to inform comprehensive models of cognitive change in MS as well as provide insights on potential targets for intervention development to help people with MS optimize cognitive function.

One limitation of this study is that the inclusion criteria require participants to be able to ambulate. The rationale for this criterion is that we would like to collect meaningful accelerometer data in order to explore the associations between physical activity and cognitive function. However, this criterion limits the generalizability of the findings to those with more significant mobility limitations.

This study has a number of notable strengths. Technology enabled assessment of day-to-day cognitive function in the lived environment has the potential to greatly improve the sensitivity and ecological validity of cognitive assessment in people with MS. The advancement of measurement sensitivity is critical as cognitive changes can be subtle and compound slowly over time; however, despite the small magnitude of these changes, individuals with MS often report distress over noticeable changes in their cognition that are not detected on standard lab-based cognitive tests. Another advantage is the intensive within-person design that allows for exploration of dynamic associations between potentially modifiable predictors of cognitive dysfunction, while accounting for “third variables” such as a person’s disease severity, age, and sex. Another strength is the inclusion of volunteers with any MS subtype and any level of cognitive function so long as they can follow study-related commands and use the smartphone.

This allows for exploring different trajectories of change over time.

Future work that capitalizes on the findings of this study and advances in assessment methods can also be used to improve treatment decision-making, including timing and type of treatment approach. We will use these findings to design and test trials of behavioral, medical, and combination therapies to prevent cognitive decline and improve cognitive functioning in people with MS. Additionally, our innovative assessment methods may also be used to improve measurement of outcomes in clinical trials of both pharmacological and non-pharmacological interventions, enriching understanding of the effects of such interventions. To our knowledge, there are few studies that track cognitive and other functional domains in MS beyond 2 years; thus, long-term outcomes will yield a rich dataset for understanding longitudinal function in persons with MS.

Acknowledgements: None.

Funding Statement: Research reported in this publication is supported by the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under Award Number R01HD102337 (MPI:Kratz/Fritz). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflicts of Interest: None declared.

Data Sharing Plan: Data sharing for this project will be coordinated by University of Michigan;

all data will be deposited into secure web-accessible data repositories. The availability of data sharing will be publicized in publications and presentations.

Author Contributions. CRediT Author Statement: AL Kratz: Conceptualization, Methodology, Investigation, Resources, Writing – Original Draft, Supervision, Project Administration, Funding acquisition. DM Ehde: Methodology, Investigation, Resources, Writing- Review & Editing, Supervision. KN Alschuler: Methodology, Investigation, Resources, Writing- Review & Editing, Supervision. K Pickup: Investigation, Writing- Review & Editing, Supervision, Project administration. K Ginell: Investigation, Writing – Review & Editing, Visualization. NE Fritz: Conceptualization, Methodology, Investigation, Resources, Writing – Original Draft, Supervision, Project Administration, Funding acquisition.

Abbreviations:

EMA: ecological momentary assessment

MS: multiple sclerosis

NIHTB: National Institutes of Health Toolbox

PDDS: Patient Determined Disease Steps

PROMIS: Patient Reported Outcomes Measurement Information System

UM: University of Michigan

WSU: Wayne State University

UW: University of Washington

NICHD: Eunice Kennedy Shriver National Institute of Child Health & Human Development

References

1. Wallin, M.T., et al., *The prevalence of MS in the United States: A population-based estimate using health claims data*. Neurology, 2019.
2. Multiple Sclerosis International Federation, *Global Economic Impact of Multiple Sclerosis*. 2010.
3. Chiaravalloti, N.D. and J. DeLuca, *Cognitive impairment in multiple sclerosis*. Lancet Neurol, 2008. **7**(12): p. 1139-51.
4. Bergendal, G., S. Fredrikson, and O. Almkvist, *Selective decline in information processing in subgroups of multiple sclerosis: an 8-year longitudinal study*. Eur Neurol, 2007. **57**(4): p. 193-202.
5. Rao, S.M., et al., *Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction*. Neurology, 1991. **41**(5): p. 685-91.
6. Grigsby, J., et al., *Working memory impairment among persons with chronic progressive multiple sclerosis*. J Neurol, 1994. **241**(3): p. 125-31.
7. Foong, J., et al., *Executive function in multiple sclerosis. The role of frontal lobe pathology*. Brain, 1997. **120** (Pt 1): p. 15-26.
8. Finlayson, M., E. Peterson, and P.N. Matsuda, *Participation as an Outcome in Multiple Sclerosis Falls-Prevention Research: Consensus Recommendation from the International MS Falls Prevention Research Network*. Int J MS Care, 2014. **16**(4): p. 171-7.
9. Grima, D.T., et al., *Cost and health related quality of life consequences of multiple sclerosis*. Mult Scler, 2000. **6**(2): p. 91-8.
10. Gunn, H.J., et al., *Identification of risk factors for falls in multiple sclerosis: a systematic review and meta-analysis*. Phys Ther, 2013. **93**(4): p. 504-13.
11. Bruce, J.M., et al., *Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition*. J Behav Med, 2010. **33**(3): p. 219-27.
12. Sumowski, J.F., et al., *Cognition in multiple sclerosis: State of the field and priorities for the future*. Neurology, 2018. **90**(6): p. 278-288.
13. Sliwinski, M.J., et al., *Reliability and Validity of Ambulatory Cognitive Assessments*. Assessment, 2018. **25**(1): p. 14-30.
14. Spooner, D.M. and N.A. Pachana, *Ecological validity in neuropsychological assessment: a case for greater consideration in research with neurologically intact populations*. Arch Clin Neuropsychol, 2006. **21**(4): p. 327-37.
15. Suchy, Y., et al., *Pitfalls in research on ecological validity of novel executive function tests: A systematic review and a call to action*. Psychol Assess, 2024. **36**(4): p. 243-261.
16. Allard, M., et al., *Mobile technologies in the early detection of cognitive decline*. PLoS One, 2014. **9**(12): p. e112197.
17. Timmers, C., et al., *Ambulant cognitive assessment using a smartphone*. Appl Neuropsychol Adult, 2014. **21**(2): p. 136-42.
18. Ram, N., et al., *Cognitive performance inconsistency: intraindividual change and variability*. Psychol Aging, 2005. **20**(4): p. 623-33.
19. West, R., et al., *Lapses of intention and performance variability reveal age-related increases in fluctuations of executive control*. Brain Cogn, 2002. **49**(3): p. 402-19.
20. Bielak, A.A., et al., *Intraindividual variability is related to cognitive change in older adults: evidence for within-person coupling*. Psychol Aging, 2010. **25**(3): p. 575-86.
21. Bielak, A.A., et al., *Intraindividual variability in reaction time predicts cognitive outcomes* 5

- years later. *Neuropsychology*, 2010. **24**(6): p. 731-41.
22. Shiffman, S., A.A. Stone, and M.R. Hufford, *Ecological momentary assessment*. *Annu Rev Clin Psychol*, 2008. **4**: p. 1-32.
 23. Sliwinski, M.J., et al., *Intraindividual change and variability in daily stress processes: findings from two measurement-burst diary studies*. *Psychol Aging*, 2009. **24**(4): p. 828-40.
 24. Sandroff, B.M., et al., *Physical activity is associated with cognitive processing speed in persons with multiple sclerosis*. *Mult Scler Relat Disord*, 2014. **3**(1): p. 123-8.
 25. Sandroff, B.M., et al., *Accuracy of StepWatch and ActiGraph accelerometers for measuring steps taken among persons with multiple sclerosis*. *PLoS One*, 2014. **9**(4): p. e93511.
 26. Sandroff, B.M., et al., *Accelerometer cut-points derived during over-ground walking in persons with mild, moderate, and severe multiple sclerosis*. *J Neurol Sci*, 2014. **340**(1-2): p. 50-7.
 27. Sandroff, B.M., R.E. Klaren, and R.W. Motl, *Relationships among physical inactivity, deconditioning, and walking impairment in persons with multiple sclerosis*. *J Neurol Phys Ther*, 2015. **39**(2): p. 103-10.
 28. Sandroff, B.M., et al., *Further validation of the Six-Spot Step Test as a measure of ambulation in multiple sclerosis*. *Gait Posture*, 2015. **41**(1): p. 222-7.
 29. Moon, Y., et al., *Monitoring gait in multiple sclerosis with novel wearable motion sensors*. *PLoS One*, 2017. **12**(2): p. e0171346.
 30. Aldughmi, M., et al., *The relationship between fatigability and sleep quality in people with multiple sclerosis*. *Mult Scler J Exp Transl Clin*, 2016. **2**: p. 2055217316682774.
 31. Al-Dughmi, M. and C.F. Siengsukon, *The relationship between sleep quality and perceived fatigue measured using the Neurological Fatigue Index in people with Multiple Sclerosis*. *Neurol Res*, 2016. **38**(11): p. 943-949.
 32. Kos, D., et al., *Measuring activity patterns using actigraphy in multiple sclerosis*. *Chronobiol Int*, 2007. **24**(2): p. 345-56.
 33. Blikman, L.J.M., et al., *Physical behaviour is weakly associated with physical fatigue in persons with multiple sclerosis-related fatigue*. *J Rehabil Med*, 2018. **50**(9): p. 821-827.
 34. Kratz, A.L., et al., *Daily Temporal Associations Between Physical Activity and Symptoms in Multiple Sclerosis*. *Ann Behav Med*, 2019. **53**(1): p. 98-108.
 35. Motl, R.W., et al., *Accelerometry as a measure of walking behavior in multiple sclerosis*. *Acta Neurol Scand*, 2013. **127**(6): p. 384-90.
 36. Gershon, R.C., et al., *NIH toolbox for assessment of neurological and behavioral function*. *Neurology*, 2013. **80**(11 Suppl 3): p. S2-6.
 37. Reuben, D.B., et al., *Motor assessment using the NIH Toolbox*. *Neurology*, 2013. **80**(11 Suppl 3): p. S65-75.
 38. Takla, T.N., et al., *Cognitive Contributors of Backward Walking in Persons with Multiple Sclerosis*. *Mult Scler Int*, 2023. **2023**: p. 5582242.
 39. Edwards, E.M., et al., *Backward walking sensitively detects fallers in persons with multiple sclerosis*. *Mult Scler Relat Disord*, 2020. **45**: p. 102390.
 40. Mohaghan, P.M., et al., *Measurement Properties of Backward Walking and its Sensitivity and Feasibility in Predicting Falls in Persons with Multiple Sclerosis*. *International Journal of MS Care*, In Press.
 41. Weintraub, S., et al., *Cognition assessment using the NIH Toolbox*. *Neurology*, 2013. **80**(11 Suppl 3): p. S54-64.
 42. Smith, A., *Symbol Digit Modalities Test (Revised)*. 1982, Los Angeles, CA: Western Psychological Services.


43. Gronwall, D. and H. Sampson, *The psychological effects of concussion*. 1974, Auckland, New Zealand: Auckland University Press.
44. Schmidt, M., *Rey Auditory Verbal Learning Test: A Handbook*. 1996, Los Angeles, CA: Western Psychological Services.
45. Richardson, J.K., et al., *Complex and Simple Clinical Reaction Times Are Associated with Gait, Balance, and Major Fall Injury in Older Subjects with Diabetic Peripheral Neuropathy*. *Am J Phys Med Rehabil*, 2017. **96**(1): p. 8-16.
46. Zivadinov, R., et al., *A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis*. *J Neurol Neurosurg Psychiatry*, 2001. **70**(6): p. 773-80.
47. Camp, S.J., et al., *Cognitive function in primary progressive and transitional progressive multiple sclerosis - A controlled study with MRI correlates*. *Brain*, 1999. **122**: p. 1341-1348.
48. Kratz, A.L., et al., *How do pain, fatigue, depressive, and cognitive symptoms relate to well-being and social and physical functioning in the daily lives of individuals with multiple sclerosis?* *Arch Phys Med Rehabil*, 2017. **98**(11): p. 2160-2166.
49. Kratz, A.L., S.L. Murphy, and T.J. Braley, *Ecological momentary assessment of pain, fatigue, depressive, and cognitive symptoms reveals significant daily variability in multiple sclerosis*. *Arch Phys Med Rehabil*, 2017. **98**(11): p. 2142-2150.
50. Kratz, A.L., S.L. Murphy, and T.J. Braley, *Pain, fatigue, and cognitive symptoms are temporally associated within but not across days in multiple sclerosis*. *Arch Phys Med Rehabil*, 2017. **98**(11): p. 2151-2159.
51. Cohen, J., *Statistical Power Analyses for the Behavioral Sciences*. 1987, Hillsdale, NJ: Lawrence Erlbaum Associates.
52. T.A.B., S., *Power and sample size in multilevel modeling*, in *Encyclopedia of Statistics in Behavioral Science*, B.S. Everitt and D.C. Howell, Editors. 2005. p. 1570-1573.
53. Amato, M.P., V. Zipoli, and E. Portaccio, *Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies*. *J Neurol Sci*, 2006. **245**(1-2): p. 41-6.
54. Camp, S.J., et al., *A longitudinal study of cognition in primary progressive multiple sclerosis*. *Brain*, 2005. **128**(Pt 12): p. 2891-8.
55. Newcombe, R.G., *Confidence Intervals for Proportions and Related Measures of Effect Size* 2012, New York, NY: CRC Press.
56. Cella, D., et al., *The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008*. *J Clin Epidemiol*, 2010. **63**(11): p. 1179-94.
57. Chung, F., et al., *High STOP-Bang score indicates a high probability of obstructive sleep apnoea*. *Br J Anaesth*, 2012. **108**(5): p. 768-75.
58. Cook, K.F., et al., *A PROMIS fatigue short form for use by individuals who have multiple sclerosis*. *Quality of Life Research*, 2012. **21**(6): p. 1021-30.
59. Askew, R.L., et al., *Evidence from diverse clinical populations supported clinical validity of PROMIS pain interference and pain behavior*. *J Clin Epidemiol*, 2016. **73**: p. 103-11.
60. Kim, J., et al., *Measurement invariance of the PROMIS pain interference item bank across community and clinical samples*. *Qual Life Res*, 2013. **22**(3): p. 501-7.
61. Amtmann, D., et al., *Development of a PROMIS item bank to measure pain interference*. *Pain*, 2010. **150**(1): p. 173-82.
62. Freynhagen, R., et al., *painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain*. *Curr Med Res Opin*, 2006. **22**(10): p. 1911-20.
63. Wolfe, F., et al., *2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria*. *Semin*

- Arthritis Rheum, 2016. **46**(3): p. 319-329.
64. Wolfe, F., et al., *The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity*. Arthritis Care Res (Hoboken), 2010. **62**(5): p. 600-10.
 65. Amtmann, D., et al., *Comparing CESD-10, PHQ-9, and PROMIS depression instruments in individuals with multiple sclerosis*. Rehabil Psychol, 2014. **59**(2): p. 220-229.
 66. Cohen, S., T. Kamarck, and R. Mermelstein, *A global measure of perceived stress*. J.Health Soc.Behav., 1983. **24**(4): p. 385-396.
 67. Miller, D.M., et al., *Validating Neuro-QoL short forms and targeted scales with people who have multiple sclerosis*. Mult Scler, 2016. **22**(6): p. 830-41.
 68. Cella, D., et al., *Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology*. Neurology, 2012. **78**(23): p. 1860-7.
 69. Becker, H., et al., *Reliability and Validity of PROMIS Cognitive Abilities and Cognitive Concerns Scales Among People with Multiple Sclerosis*. Int J MS Care, 2014. **16**(1): p. 1-8.
 70. Becker, H., et al., *An initial investigation of the reliability and validity of the Compensatory Cognitive Strategies Scale*. Neuropsychol Rehabil, 2019. **29**(5): p. 739-753.
 71. Hohol, M.J., E.J. Orav, and H.L. Weiner, *Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression*. Mult Scler, 1999. **5**(5): p. 349-54.
 72. Yardley, L., et al., *Development and initial validation of the Falls Efficacy Scale-International (FES-I)*. Age Ageing, 2005. **34**(6): p. 614-9.
 73. Landers, M.R., et al., *Development of a scale to assess avoidance behavior due to a fear of falling: the Fear of Falling Avoidance Behavior Questionnaire*. Phys Ther, 2011. **91**(8): p. 1253-65.
 74. Takla, T.N., et al., *Scale development to evaluate differences between concern about falling and fear of falling: the concern and fear of falling evaluation*. Front Psychol, 2024. **15**: p. 1336078.
 75. Gryczynski, J., et al., *Validation of the TAPS-1: A Four-Item Screening Tool to Identify Unhealthy Substance Use in Primary Care*. J Gen Intern Med, 2017. **32**(9): p. 990-996.
 76. McNeely, J., et al., *Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) Tool for Substance Use Screening in Primary Care Patients*. Ann Intern Med, 2016. **165**(10): p. 690-699.
 77. Wu, L.T., et al., *Design of the NIDA clinical trials network validation study of tobacco, alcohol, prescription medications, and substance use/misuse (TAPS) tool*. Contemp Clin Trials, 2016. **50**: p. 90-7.
 78. Horton, M., et al., *Validation of a self-report comorbidity questionnaire for multiple sclerosis*. Neuroepidemiology, 2010. **35**(2): p. 83-90.
 79. Gosling, S.D., P.J. Rentfrow, and W.B.J. Swann, *A very brief measure of the big-five personality domains*. Journal of Research in Personality, 2003. **37**(6): p. 504-528.
 80. Applebaum, J.W., et al., *The Impact of Sustained Ownership of a Pet on Cognitive Health: A Population-Based Study*. J Aging Health, 2023. **35**(3-4): p. 230-241.

Supplementary Files

Figures


The Wear-IT application landing page (A), morning survey landing page (B), self-reported wake up time (C), an item from the perceived cognitive function scale (D), an item from the depressed mood scale (E), and the survey of substance consumption (F).



The ActiGraph wGT3X-BT triaxial accelerometer.



Symbol Search landing page (A), test instructions (B and C), and examples of a “non-lure trial” (D; where neither symbol in the incorrect pair on the bottom appears in the pairs above) and a “lure trial” (E; where one of the symbols in the incorrect pair on the bottom appears in a pair above).



Dot Memory Test landing page (A), instructions (B), E's and F's distraction phase (C), and response page (D).

A Grid Memory Activity


On the next screen, you will be presented with instructions for the **Grid Memory** activity.

Press **Next** to continue.

Next

B Instructions

During this activity, you will see 3 red dots appear briefly on a grid.



You will be asked to try to remember their locations!

Press **NEXT** to continue.

Next

C Grid Memory Activity

Next, you will see a screen full of Es and Fs, like the example below:

E	E	E	F	E
E	E	F	E	E
E	E	E	E	E
E	F	E	E	E
E	E	E	E	E
E	E	F	E	E

You will be asked to tap all the Fs as quickly as you can!


Press **Next** to continue

Next

D Grid Memory Activity

When the empty grid appears, you will be asked to place dots where you remember seeing them by tapping on the grid.

Where were the dots?



DONE

Hint: You can tap and untap to move the dots.

Press **Next** to continue.

Next

Multimedia Appendixes

Detailed Description of CogDetect-MS Self-Report Measures.

URL: <http://asset.jmir.pub/assets/672088d41d3950d1eec6fdb55b355b1b.docx>

Detailed Description of CogDetect-MS Performance-Based Measures.

URL: <http://asset.jmir.pub/assets/76c0ec646ca310ec47a16549869bd36a.docx>

Detailed Description of CogDetect-MS Ambulatory Self-Report Measures.

URL: <http://asset.jmir.pub/assets/1878cf1bbc67725aa468923f62e45dad.docx>

